Stocksigma LogoStocksigma Logo

Dr. Reddy’s Clarifies US FDA Tentative Approval for Generic HIV Drug Lenacapavir

Dr. Reddy’s Laboratories confirmed media reports regarding US FDA tentative approval for its twice-yearly injectable lenacapavir, aimed at expanding

Dr. Reddy’s Clarifies US FDA Tentative Approval for Generic HIV Drug Lenacapavir

Dr Reddys Laboratories Ltd · Others (Uncategorized) · 04 Nov 2026, 5:15 pm

Dr. Reddy’s Clarifies US FDA Tentative Approval for Generic HIV Drug Lenacapavir Dr. Reddy’s Laboratories confirmed media reports regarding US FDA tentative approval for its twice-yearly injectable lenacapavir, aimed at expanding generic HIV prevention access across 120 countries outside the US. Responding to a BSE clarification request dated 3rd Nov'26, the company stated the news relates to its 2nd Nov'26 press release. Dr. Reddy’s highlighted that the development does not constitute a material event or require disclosure under Regulation 30 of SEBI Listing Regulations, maintaining adherence to all mandatory disclosure compliance requirements.

Original exchange filing (PDF)

More announcements from Dr Reddys Laboratories Ltd

All Dr Reddys Laboratories Ltd announcements